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Background
Cytogenetic abnormalities (CAs) have been reported frequently in patients with otherwise 
typical aplastic anemia (AA), but their implications in the prognosis and in the evolution 
to hematologic malignancies are controversial.
Methods
We retrospectively analyzed 127 adult AA patients who had successful cytogenetic analy-
sis at initial diagnosis.
Results
The patients were classified into 3 groups according to the initial and follow-up results 
of cytogenetic profiles. Group 1 included patients who had persistent AA with normal 
cytogenetic profiles (N=117); Group 2, those who had a normal cytogenetic profile at 
initial diagnosis but later acquired CA (N=4, 3.1%); and Group 3, those who had CA at 
the initial diagnosis, regardless of follow-up cytogenetic status (N=6,4.7%). In Group 2, 
2 patients later developed CA without progression to acute myeloid leukemia (AML) or 
myelodysplastic syndrome (MDS); the other 2 patients later progressed to AML. None 
of the patients in Group 3 progressed to AML or MDS. There was no significant difference 
in overall survival between Groups 1 and 3.
Conclusion
AA patients with CA at initial diagnosis or follow-up may not be at greater risk for evolution 
to AML or MDS, or show shorter survival periods. Prospective studies and a larger patient 
samples are needed to establish the clinical relevance of CA.
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INTRODUCTION
  The survival of acquired aplastic anemia (AA) patients has 
shown a marked improvement due to immunosuppressive 
therapy (IST) and bone marrow transplantation (BMT). This 
improved survival creates the opportunity for observing the 
long-term course of bone marrow failure syndrome [1, 2]. 
Technological advances in methods for obtaining complete 
chromosomal preparations during metaphase and identifying 
cytogenetics (e.g., various banding techniques, fluorescent 
in situ hybridization) have allowed cytogenetic studies to 
be included in the diagnostic workup and have contributed 
prognostic value in several hematological disorders [3].
  Cytogenetic abnormalities (CAs) can be observed at initial 
diagnosis of AA, may develop spontaneously, or may develop 
after years of IST [4-6]. Genomic instability does not appear 
to be a rare event in AA, since transient or permanent chro-
mosomal aberrations have been reported with various onset 
times. Hence, numerous attempts have been made to de-
termine the clinical implications of CA in AA related to 
disease prognosis and to possible evolution into clonal hema-
tologic disorders [7-13]. Some researchers contend that since 
AA evolves into acute myeloid leukemia (AML) or myelodys-
plastic syndrome (MDS) in approximately 3-13% of all cases 
[7], the clonal cytogenetic events in AA over the course Korean J Hematol 2010;45:242-6.
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of the disease, as well as at diagnosis, are strongly suggestive 
of its preleukemic nature [14-17]. Young patients with hypo-
plastic MDS, especially those with normal cytogenetics, re-
sponded well to IST, which suggests that AA and MDS may 
share the same immune pathophysiology for the develop-
ment of pancytopenia [18]. Others insist that the CAs in 
AA are associated neither with the natural course nor with 
the premalignant characteristics of the disease [8].
　The paucicellularity of the bone marrow makes differential 
diagnosis among hypoplastic MDS [19], hypoplastic AML 
[20], and AA difficult. Some insist that typical CA, regardless 
of bone marrow morphology, could discriminate hypoplastic 
MDS from AA [21], but others consider hypoplastic bone 
marrow with discrete dysplastic features as hypoplastic MDS 
[22]. The discrimination between AA and preleukemia is 
important, because they have different natural courses and 
warrant different treatment strategies [23]. Therefore, our 
aim was to determine the significance of CA in adult acquired 
AA by investigating patient survival and progression to other 
hematologic diseases. 
MATERIALS AND METHODS 
  We retrospectively observed 222 adult patients with ac-
quired AA, who were treated in 4 hospitals located in Busan, 
South Korea, between January 1995 and March 2009. Patient 
information was obtained by reviewing medical records, ac-
cording to the protocols approved by the Institutional Review 
Board (IRB number: 09-10-90). The results of cytogenetic 
studies were available for 152 patients.
  Chromosomal analysis was performed on 24-48 h syn-
chronized cultures of bone marrow cells. Karyotyping was 
done using standard Trypsin-Giemsa banding methods. 
Diagnosis and assessment of the disease were based on the 
modified Camitta’s criteria. Severe AA required at least 2 
of the following criteria: less than 0.5×10
9 neutrophils/L, 
less than 20×10
9 platelets/L, or less than 1% reticulocytes 
(corrected for hematocrit) in the peripheral blood; marked 
hypocellularity (less than 25% of normal cellularity) or mod-
erate hypocellularity (25-50% of normal cellularity), with 
less than 30% hematopoietic cells remaining in the bone 
marrow aspirate [24]. Non-severe AA was defined by hypo-
cellular bone marrow with pancytopenia (without other cri-
teria of severe AA). Morphologically hypoplastic bone mar-
row with dysplastic cells was considered as hypoplastic MDS 
and excluded. Clonal CA were defined as 2 or more cells 
showing the same chromosomal gain or structural abnormal-
ity, or 3 or more cells with the same chromosomal loss. 
At follow-up, the presence of only 1 abnormal cell was 
considered sufficient to demonstrate clonal abnormality [25]. 
A cytogenetic study was considered to have failed, if fewer 
than 5 metaphases were seen despite inspection of at least 
4 slides. Of the 152 patients with available cytogenetic stud-
ies, 25 patients (15%) were excluded from the analysis be-
cause of a lack of meaningful results (e.g., culture failure 
and insufficient number of metaphases). 
  We grouped patients according to the CA detected at 
initial diagnosis or at follow-up and according to progression 
to other hematologic disorders. Group 1 included patients 
with a normal karyotype at diagnosis and during follow-up, 
without evolution into clonal hematologic disorders. Patients 
in Group 2 demonstrated a normal cytogenetic profile at 
initial diagnosis, but acquired clonal evolution later, and 
Group 3 included patients with CA at initial diagnosis, re-
gardless of follow-up cytogenetics. 
  Means and medians were calculated when appropriate, 
continuous variables were compared by the student t-test, 
and categorical variables were analyzed by the chi-square 
test. The cumulative survival was estimated by the 
Kaplan-Meier method. The survival rates of patients with 
normal and abnormal cytogenetics were compared by the 
log-rank test.
RESULTS
  We analyzed data from 127 patients on whose samples 
successful culture had been performed. The median fol-
low-up period was 46.8 months (range, 0.3-165.8 months). 
One hundred and twenty-one patients (95.3%) had normal 
karyotypes and 6 (4.7%) showed abnormal karyotypes at 
the first chromosomal analysis. Other than sex, there were 
no significant differences in baseline characteristics between 
the normal and abnormal karyotype groups. The median 
age of the latter group was 53 years (range, 25-70), compared 
to 47 years (range, 17-83) for those patients with a normal 
karyotype. All 6 patients with abnormal karyotypes were 
male, and the male to female ratio was 1：1 in the remaining 
patients. The ratio of severe AA (SAA) to non-severe AA 
(NSAA) for patients with abnormal karyotypes at initial diag-
nosis was 5：1, as compared to 1.4：1 in the remaining 
patients. The mean bone marrow cellularity was 13.3% vs. 
15.8%, and the number of mean-analyzed cells was 16.4 
vs. 18.0 for the normal and abnormal karyotype groups, 
respectively. 
  Patients with abnormal karyotypes at diagnosis showed 
no evolution to hematologic disorders; however, of those 
with normal cytogenetics at diagnosis, 2 progressed to AML 
with clonal evolution (Table 1). The median survival accord-
ing to the severity of AA was 103.3 months in SAA vs. 
not yet reached in NSAA (P=0.0014) (Fig. 1).
  Among the patients with normal cytogenetics at initial 
diagnosis, 117 patients exhibited normal cytogenetics, while 
continuing to show AA during follow-up (Group 1). Patients 
in Group 1 were treated with IST or BMT in case of SAA.
  The 4 patients in Group 2 demonstrated normal cytoge-
netics at initial diagnosis but developed CA during the fol-
low-up period. Of these, 2 did not progress to AML or MDS 
at the time of clonal evolution. They showed monosomy 
4 and monosomy 7 after 126.0 and 17.7 months of supportive 
care, respectively. Both were females (25 and 68 years old) 
at diagnosis, respectively. At initial diagnosis, the patient 
with monosomy 4 was found to have NSAA, and the patient Korean J Hematol 2010;45:242-6.
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Fig. 1. Survival curves according to the severity of patients. The median
survival was 103.3 months in SAA vs. not yet reached in NSAA (P= 
0.0014).
Table 1. Characteristics of eligible patients.
Normal 
karyotype
Abnormal
karyotype
P
Patient (%) 121 (95.3) 6 (4.7)
Median age at diagnosis (range) 53 (25-70) 47 (17-83)
Sex
M6 0 6
0.03
F6 1 0
Severity
SAA 70 5
0.4
NSAA 51 1
Mean BM cellularity (%) 13.3 15.8 0.45
Mean analyzed cells 16.35 18 0.41
Patients who progressedto AML 2 0
Abbreviations: M, male; F, female; SAA, severe aplastic anemia; 
NSAA, non-severe aplastic anemia; BM, bone marrow; AML, acute
myeloid leukemia; MDS, myelodysplastic syndrome.
Table 2. Characteristics of patients with cytogenetic abnormalities or progression to hematologic malignancies.
Age/ % of  % of  Follow- Other Follow-up 
Karyo- Treatment
UPN Group Sex analyzed  Severity Treatment analyzed up hematologic  Survival time
type response
(years) metaphases metaphases cytogenetics diseases (months)
1 2 25/F 25 46,XX NSAA No NA 5/25 45,XX,-4 No Alive 150.97
2 2 68/F 20 46.XX SAA No NA 7/20 45,XX,-7 No Alive 46.17
3 2 33/M 20 46,XY SAA ATG/CSA/ No 12/20 46,XY,t(1;11) AML Death 54.6
Methyl Pd (q21;q23) 
4 2 60/M 9 46,XY NSAA No No 18/18 Complex
b) AML Death 5.23
5 3 51/M 20/20 47,XY,+11 SAA ATG/CSA/ No 1/2 +1
c) No Alive 83.90 
Methyl Pd
6 3 62/M 5/20 t(2;9)/ SAA ATG/CSA/ No NA No Death 16.8
t(1;20)
a) Methyl Pd
7 3 35/M 19/20 47,XY,+8 SAA ATG/CSA No NA No Death 16.4
8 3 70/M 6/16 45,XX,-Y SAA G-CSF No NA No Death 3.3
9 3 55/M 3/15 47,XY,+8 SAA No NA NA No Alive 66.4
10 3 25/M 20/20 46,XY,t(22;?) NSAA No NA 　 NA no Alive 53.57
(q11.2;?)
11 49/F Culture failure NA SAA ATG No 9/10 47,XX,+11 AML Death 25.1
12 　 56/F Culture failure NA SAA Oxy No 7/10 t(1;6)
d) MDS Death 34.6
a)46,XY,t(2;9)(q33;p24)[3]/46,XY,t(1;20)(p10;q10)[2], 
b)46,XY, t(6;7)(q10;q10),?t(11;18)(q13;q21),der(21)t(21;22)(q22;q11.2),-22,+2 mar, 
c)46,XY,?+1,?der(1;7)(q10;p10)[1], 
d)46,XX,der(6)t(1;6)(q12;p25).
Abbreviations: NA, not-available; ATG, anti thymocyte globlulin; CSA, cyclosporine; Methyl Pd, methylprednisolone; G-GCF, granulocyte 
colony-stimulating factor; Oxy, oxymetholone; Other hematologic diseases, evolution into other hematologic diseases; AML, acute myeloid 
leukemia; MDS, myelodysplastic syndrome.
with monosomy 7, SAA. They are still alive, having survival 
times of 151.0 and 46.2 months, respectively. They do not 
require transfusions, nor have they developed any other 
hematologic malignancies. The other 2 patients progressed 
to AML with structural CA during follow-up assessment. 
One of these patients showed complex CA after 2.6 months 
of supportive care, and the other patient was characterized 
b y  t ( 1 ; 1 1 ) ,  5 1 . 7  m o n t h s  a f t e r  I S T .  T h e y  r e c e i v e d  c h e m o -
therapy for AML, but both died of sepsis 3 months after 
AML diagnosis. The median intervals between the secondary 
clonal hematologic disorders and death were 2.6 and 2.9 
months, respectively, and their survival time was 5.2 and 
54.6 months, respectively.
  The 6 patients in Group 3 were diagnosed with AA, and 
all demonstrated CA at initial diagnosis. CA was found to 
be +8 in 2 cases and +11 in 1 case, -Y in 1 case, t(2;9)/t(1;20) 
in 1 case, and t(22;?) in the remaining case. The patient 
with +11 received IST and showed a CA of +1 after 23 
months. He is still alive and does not require transfusions. 
The patient with t(2;9)/t(1;20) and 1 of the patients with 
+8 also received IST, but died due to sepsis after 16.4 and 
16.8 months, respectively. The patient who had -Y was treat-Korean J Hematol 2010;45:242-6.
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ed with granulocyte colony-stimulating factor (G-CSF) only, 
and the patient died of sepsis after 3.3 months. The remaining 
patient with +8 and the patient with t(22;?) received inter-
mittent transfusions and supportive care, and both are still 
alive. None of the patients in Group 3 progressed to AML 
or MDS (Table 2). Patients in Group 1 did not reach the 
median survival time; their mortality rates were 0.19 at 1 
year, 0.27 at 2 years, and 0.53 at 5 years. Patients in Group 
3 showed a median survival of 16.8 months (P=0.37, com-
pared with Group 1). 
  Two patients, who were not included in the analysis be-
cause of an unsuccessful culture at initial diagnosis, pro-
gressed to AML or MDS. One of the patients progressed 
to AML with +11 after 12.8 months of IST and died of 
sepsis 12.2 months after AML diagnosis. The other patient 
progressed to MDS with t(1;6) after 28.3 months of oxy-
metholone treatment but died of chronic GVHD 6.3 months 
after BMT. 
DISCUSSION
  Previous studies have estimated CA and genomic in-
stability of AA (at diagnosis or at follow-up) in approximately 
4-15% of all cases, but the clinical significance of CA in 
AA is still unknown [4-6]. In our study, a review of bone 
marrow pathology and of cytogenetics in patients typically 
presenting AA by performing peripheral cytopenia and mar-
row pathology showed that the majority of patients had 
normal cytogenetics (Group 1), and only 6 patients presented 
with clonal CA at initial diagnosis (4.7%) (Group 3). Although 
the number of patients analyzed in this study was too small 
and the observation period too short to generalize, the clinical 
characteristics and the survival data trends demonstrate a 
male predominance, an increasing severity, and a tendency 
of shorter survival in Group 3 patients than in Group 1 
patients. 
  CAs (e.g., +8, -Y, +11, other structural abnormalities) are 
commonly associated with AML or MDS [26, 27]. These 
CAs were also observed concurrent with AA diagnosis in 
our study. Although only 1 patient in Group 3 underwent 
repeated bone marrow examinations, a review of repeated 
peripheral blood smear revealed that none of the patients 
progressed to other hematologic malignancies. Two patients 
in Group 2 later developed numerical CA (monosomy 4 
and monosomy 7), but they did not develop AML or MDS. 
Although the number of patients in Groups 2 and 3 is too 
small to form conclusions, the clonal cytogenetic events in 
AA patients does not necessarily imply that AA is a pre-
leukemic syndrome, nor that CA presenting with AA predicts 
subsequent AML or MDS development (regardless of IST). 
In addition, the full leukemogenic implications of +8 and 
−Y are undetermined; however, sole +8 is an insufficient 
condition for leukemogenesis [28], and the loss of the Y 
chromosome has been observed in the general elderly pop-
ulation, with an incidence similar to that reported for AML 
or MDS [29]. The true leukemogenic potential of these chro-
mosomes needs to be investigated. The 2 patients in Group 
2, who developed monosomy 7 and monosomy 4 during 
follow-up, showed long-term survival in our study. Although 
the number of patients is too small and the lack of follow-up 
cytogenetics in patients with initial CA makes it difficult 
to generalize, the acquisition of monosomal karyotypes in 
otherwise typical AA patients may not necessarily mean 
a poorer prognosis. 
  CAs may be adopted by some experts to discriminate be-
tween AA, hypocelluar AML, and hypocellular MDS [30]. 
Hypocellular bone marrow may obscure the diagnoses of 
AA and hypoplastic MDS or AML in cases where cytogenetics 
and molecular methods are not available at diagnosis (e.g., 
because of a culture failure). In some cases with pancytopenia, 
morphologically diagnosed AA with insufficient cytogenetics 
may progress to hematologic malignancies. Therefore, re-
peated follow-up, including bone marrow examination and 
cytogenetic analysis, is required to identify misdiagnosed 
cases. Moreover, SAA patients whose disease converts to 
non-severe AA, or vice versa, and who become independent 
of transfusion, need repeated examination of their bone mar-
row for the monitoring of potential evolution to other hema-
tologic malignancies. 
  CAs are rarely seen in AA. The analysis of 127 AA patients 
suggests that, despite the small number of patients with 
CA in AA, CA did not affect the survival or evolution into 
other hematologic malignancies. As previously reported [8], 
adult non-severe AA patients may have CA at initial diagnosis 
or at follow-up. More patients and prospective studies are 
needed to establish the clinical significance of CA in AA.
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